Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
IN8bio Inc Market Cap
The IN8bio Inc (INAB) share price is expected to increase by 1432.26% over the next year. This is based on calculating the average 12-month share price estimate provided by 4 stock analysts who have covered INAB. Price targets range from $1.5 at the low end to $8 at the high end. The current analyst consensus for INAB is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
About 4 Wall Street analysts have assigned INAB 3 buy ratings, 1 hold ratings, and 0 sell ratings. This means that analysts expect IN8bio Inc to outperform the market. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on INAB. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
These are the latest 20 analyst ratings of INAB.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Swayampakula Ramakanth HC Wainwright & Co. | Buy | $8 | Maintains | Nov 13, 2024 |
| Soumit Roy Jones Trading | Hold | Downgrade | Aug 12, 2024 | |
| Soumit Roy Jones Trading | Buy | $6.5 | Maintains | Jun 14, 2024 |
| Swayampakula Ramakanth HC Wainwright & Co. | Buy | $12.5 | Reiterates | Jun 14, 2024 |
| Swayampakula Ramakanth HC Wainwright & Co. | Buy | $12.5 | Reiterates | Jun 4, 2024 |
| Swayampakula Ramakanth HC Wainwright & Co. | Buy | $12.5 | Maintains | May 13, 2024 |
| Swayampakula Ramakanth HC Wainwright & Co. | Buy | $14 | Reiterates | Apr 10, 2024 |
| Yale Jen Laidlaw & Co. | Buy | $7.5 | Initiates | Mar 18, 2024 |
| Swayampakula Ramakanth HC Wainwright & Co. | Buy | $14 | Reiterates | Mar 15, 2024 |
| Soumit Roy JonesTrading | Buy | $5 | Initiates | Mar 13, 2024 |
| Swayampakula Ramakanth HC Wainwright & Co. | Buy | $14 | Reiterates | Nov 13, 2023 |
| Swayampakula Ramakanth HC Wainwright & Co. | Buy | $14 | Reiterates | Aug 11, 2023 |
| Tony Butler EF Hutton | Buy | $8 | Reiterates | Jun 5, 2023 |
| Swayampakula Ramakanth HC Wainwright & Co. | Buy | $14 | Reiterates | May 16, 2023 |
| Swayampakula Ramakanth HC Wainwright & Co. | Buy | $14 | Reiterates | Apr 26, 2023 |
| Mara Goldstein Mizuho | Buy | $12 | Reiterates | Apr 24, 2023 |
| Tony Butler EF Hutton | Buy | $8 | Maintains | Apr 17, 2023 |
| Swayampakula Ramakanth HC Wainwright & Co. | Buy | $14 | Reiterates | Mar 31, 2023 |
| Tony Butler EF Hutton | Buy | $8 | Reiterates | Mar 31, 2023 |
| Tony Butler EF Hutton | Buy | $8 | Initiates | Mar 29, 2023 |
When did it IPO
2021
Staff Count
39
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Mr. Tai-Wei Ho
Market Cap
$23.0M
In 2023, INAB generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that INAB's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Tue, 12 Nov 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - IN8bio, Inc. reported that INB-100 has shown 100% complete remission in AML patients and received FDA guidance for a registrational trial. They raised $11.6M in October 2024, extending cash runway through 2025.
Why It Matters - Positive clinical results for INB-100 in AML and FDA guidance suggest potential for significant market approval, while new funding extends operational stability, enhancing growth prospects for IN8bio.
Wed, 04 Sep 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - INB-100 shows 100% progression-free survival in AML patients as of August 30, 2024, with ongoing enrollment in its trial. INB-400's Phase 2 trial is suspended, monitoring continues for long-term outcomes.
Why It Matters - The focus on INB-100 shows potential for strong value creation in AML treatment, while the suspension of INB-400 may signal challenges, impacting investor confidence and stock performance.
Thu, 29 Aug 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - IN8bio, Inc. (Nasdaq: INAB) announced CEO William Ho will present at H.C. Wainwright's 26th Annual Global Investment Conference on August 29, 2024.
Why It Matters - IN8bio's presentation by CEO William Ho may signal advancements in their gamma-delta T cell therapies, potentially influencing stock performance and investor sentiment in biopharma.
Mon, 12 Aug 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - The FDA provided guidance for INB-100, an allogeneic gamma-delta T cell therapy for AML, with an IND submission expected in Q1 2025. Early data shows improved survival, advancing to Phase 2 trials.
Why It Matters - FDA guidance on INB-100's path for AML could enhance its market potential. Positive early data and progression to Phase 2 suggest strong prospects, impacting future valuations and investor interest.
Mon, 24 Jun 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - IN8bio, Inc. (Nasdaq: INAB) CEO William Ho will speak at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference on June 25, 2024, at 2:30 p.m. ET.
Why It Matters - William Ho's participation in a prominent conference highlights IN8bio's focus on innovative therapies, potentially boosting investor confidence and interest in the company's future prospects.
Thu, 13 Jun 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - All treated leukemia patients (10/10) achieved complete remission after one year, including high-risk cases. Allogeneic gamma-delta T cells showed long-term persistence post-treatment.
Why It Matters - The complete remission in all treated leukemia patients highlights the potential of the innovative therapy, suggesting strong future market prospects and possible competitive advantages in oncology.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
